ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Recurrent Glioblastoma Multiforme Treatment Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-32C6068
Home | Market Reports | Health| Health Conditions| Cancer
Global Recurrent Glioblastoma Multiforme Treatment Market Insights Forecast to 2028
BUY CHAPTERS

Global Recurrent Glioblastoma Multiforme Treatment Market Research Report 2025

Code: QYRE-Auto-32C6068
Report
January 2025
Pages:94
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol Myers Squibb Company
Cantex Pharmaceuticals Inc
Cavion llc
Celldex Therapeutics Inc
Coherus BioSciences Inc
Cortice Biosciences, Inc.
Eisai Co Ltd
Eli Lilly and Company
EnGeneIC
ERC Belgium SA
GenSpera
Genzyme Corporation
GW Pharmaceuticals Plc
ImmunoCellular Therapeutics, Ltd.

Recurrent Glioblastoma Multiforme Treatment Market Size

The global market for Recurrent Glioblastoma Multiforme Treatment was valued at US$ 495 million in the year 2024 and is projected to reach a revised size of US$ 737 million by 2031, growing at a CAGR of 5.9% during the forecast period.

Recurrent Glioblastoma Multiforme Treatment Market

Recurrent Glioblastoma Multiforme Treatment Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Recurrent Glioblastoma Multiforme Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recurrent Glioblastoma Multiforme Treatment.
The Recurrent Glioblastoma Multiforme Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Recurrent Glioblastoma Multiforme Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recurrent Glioblastoma Multiforme Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Recurrent Glioblastoma Multiforme Treatment Market Report

Report Metric Details
Report Name Recurrent Glioblastoma Multiforme Treatment Market
Accounted market size in year US$ 495 million
Forecasted market size in 2031 US$ 737 million
CAGR 5.9%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • AU-105
  • Axitinib
  • AXL-1717
  • AZD-7451
  • Others
Segment by Application
  • Hospital
  • Clinic
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Cantex Pharmaceuticals, Inc., Cavion LLC, Celldex Therapeutics, Inc., Coherus BioSciences, Inc., Cortice Biosciences, Inc., Eisai, Eli Lilly and Company, EnGeneIC Ltd, ERC Belgium SA, GenSpera, Inc., Genzyme Corporation, GW Pharmaceuticals Plc, ImmunoCellular Therapeutics, Ltd.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Recurrent Glioblastoma Multiforme Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Recurrent Glioblastoma Multiforme Treatment Market growing?

Ans: The Recurrent Glioblastoma Multiforme Treatment Market witnessing a CAGR of 5.9% during the forecast period 2025-2031.

What is the Recurrent Glioblastoma Multiforme Treatment Market size in 2031?

Ans: The Recurrent Glioblastoma Multiforme Treatment Market size in 2031 will be US$ 737 million.

Who are the main players in the Recurrent Glioblastoma Multiforme Treatment Market report?

Ans: The main players in the Recurrent Glioblastoma Multiforme Treatment Market are Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Cantex Pharmaceuticals, Inc., Cavion LLC, Celldex Therapeutics, Inc., Coherus BioSciences, Inc., Cortice Biosciences, Inc., Eisai, Eli Lilly and Company, EnGeneIC Ltd, ERC Belgium SA, GenSpera, Inc., Genzyme Corporation, GW Pharmaceuticals Plc, ImmunoCellular Therapeutics, Ltd.

What are the Application segmentation covered in the Recurrent Glioblastoma Multiforme Treatment Market report?

Ans: The Applications covered in the Recurrent Glioblastoma Multiforme Treatment Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Recurrent Glioblastoma Multiforme Treatment Market report?

Ans: The Types covered in the Recurrent Glioblastoma Multiforme Treatment Market report are AU-105, Axitinib, AXL-1717, AZD-7451, Others

Recommended Reports

Cancer Drug Markets

Oncology Treatment Technologies

Neuro & Rare Oncology

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 AU-105
1.2.3 Axitinib
1.2.4 AXL-1717
1.2.5 AZD-7451
1.2.6 Others
1.3 Market by Application
1.3.1 Global Recurrent Glioblastoma Multiforme Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Recurrent Glioblastoma Multiforme Treatment Market Perspective (2020-2031)
2.2 Global Recurrent Glioblastoma Multiforme Treatment Growth Trends by Region
2.2.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Recurrent Glioblastoma Multiforme Treatment Historic Market Size by Region (2020-2025)
2.2.3 Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Region (2026-2031)
2.3 Recurrent Glioblastoma Multiforme Treatment Market Dynamics
2.3.1 Recurrent Glioblastoma Multiforme Treatment Industry Trends
2.3.2 Recurrent Glioblastoma Multiforme Treatment Market Drivers
2.3.3 Recurrent Glioblastoma Multiforme Treatment Market Challenges
2.3.4 Recurrent Glioblastoma Multiforme Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recurrent Glioblastoma Multiforme Treatment Players by Revenue
3.1.1 Global Top Recurrent Glioblastoma Multiforme Treatment Players by Revenue (2020-2025)
3.1.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Recurrent Glioblastoma Multiforme Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Recurrent Glioblastoma Multiforme Treatment Revenue
3.4 Global Recurrent Glioblastoma Multiforme Treatment Market Concentration Ratio
3.4.1 Global Recurrent Glioblastoma Multiforme Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recurrent Glioblastoma Multiforme Treatment Revenue in 2024
3.5 Global Key Players of Recurrent Glioblastoma Multiforme Treatment Head office and Area Served
3.6 Global Key Players of Recurrent Glioblastoma Multiforme Treatment, Product and Application
3.7 Global Key Players of Recurrent Glioblastoma Multiforme Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Type
4.1 Global Recurrent Glioblastoma Multiforme Treatment Historic Market Size by Type (2020-2025)
4.2 Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Type (2026-2031)
5 Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Application
5.1 Global Recurrent Glioblastoma Multiforme Treatment Historic Market Size by Application (2020-2025)
5.2 Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Recurrent Glioblastoma Multiforme Treatment Market Size (2020-2031)
6.2 North America Recurrent Glioblastoma Multiforme Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2020-2025)
6.4 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Recurrent Glioblastoma Multiforme Treatment Market Size (2020-2031)
7.2 Europe Recurrent Glioblastoma Multiforme Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2020-2025)
7.4 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size (2020-2031)
8.2 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size (2020-2031)
9.2 Latin America Recurrent Glioblastoma Multiforme Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2020-2025)
9.4 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size (2020-2031)
10.2 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Boehringer Ingelheim GmbH
11.1.1 Boehringer Ingelheim GmbH Company Details
11.1.2 Boehringer Ingelheim GmbH Business Overview
11.1.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Introduction
11.1.4 Boehringer Ingelheim GmbH Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
11.1.5 Boehringer Ingelheim GmbH Recent Development
11.2 Boston Biomedical, Inc.
11.2.1 Boston Biomedical, Inc. Company Details
11.2.2 Boston Biomedical, Inc. Business Overview
11.2.3 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.2.4 Boston Biomedical, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
11.2.5 Boston Biomedical, Inc. Recent Development
11.3 Bristol-Myers Squibb Company
11.3.1 Bristol-Myers Squibb Company Company Details
11.3.2 Bristol-Myers Squibb Company Business Overview
11.3.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Introduction
11.3.4 Bristol-Myers Squibb Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
11.3.5 Bristol-Myers Squibb Company Recent Development
11.4 Cantex Pharmaceuticals, Inc.
11.4.1 Cantex Pharmaceuticals, Inc. Company Details
11.4.2 Cantex Pharmaceuticals, Inc. Business Overview
11.4.3 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.4.4 Cantex Pharmaceuticals, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
11.4.5 Cantex Pharmaceuticals, Inc. Recent Development
11.5 Cavion LLC
11.5.1 Cavion LLC Company Details
11.5.2 Cavion LLC Business Overview
11.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Introduction
11.5.4 Cavion LLC Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
11.5.5 Cavion LLC Recent Development
11.6 Celldex Therapeutics, Inc.
11.6.1 Celldex Therapeutics, Inc. Company Details
11.6.2 Celldex Therapeutics, Inc. Business Overview
11.6.3 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.6.4 Celldex Therapeutics, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
11.6.5 Celldex Therapeutics, Inc. Recent Development
11.7 Coherus BioSciences, Inc.
11.7.1 Coherus BioSciences, Inc. Company Details
11.7.2 Coherus BioSciences, Inc. Business Overview
11.7.3 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.7.4 Coherus BioSciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
11.7.5 Coherus BioSciences, Inc. Recent Development
11.8 Cortice Biosciences, Inc.
11.8.1 Cortice Biosciences, Inc. Company Details
11.8.2 Cortice Biosciences, Inc. Business Overview
11.8.3 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.8.4 Cortice Biosciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
11.8.5 Cortice Biosciences, Inc. Recent Development
11.9 Eisai
11.9.1 Eisai Company Details
11.9.2 Eisai Business Overview
11.9.3 Eisai Recurrent Glioblastoma Multiforme Treatment Introduction
11.9.4 Eisai Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
11.9.5 Eisai Recent Development
11.10 Eli Lilly and Company
11.10.1 Eli Lilly and Company Company Details
11.10.2 Eli Lilly and Company Business Overview
11.10.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Introduction
11.10.4 Eli Lilly and Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
11.10.5 Eli Lilly and Company Recent Development
11.11 EnGeneIC Ltd
11.11.1 EnGeneIC Ltd Company Details
11.11.2 EnGeneIC Ltd Business Overview
11.11.3 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Introduction
11.11.4 EnGeneIC Ltd Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
11.11.5 EnGeneIC Ltd Recent Development
11.12 ERC Belgium SA
11.12.1 ERC Belgium SA Company Details
11.12.2 ERC Belgium SA Business Overview
11.12.3 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Introduction
11.12.4 ERC Belgium SA Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
11.12.5 ERC Belgium SA Recent Development
11.13 GenSpera, Inc.
11.13.1 GenSpera, Inc. Company Details
11.13.2 GenSpera, Inc. Business Overview
11.13.3 GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.13.4 GenSpera, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
11.13.5 GenSpera, Inc. Recent Development
11.14 Genzyme Corporation
11.14.1 Genzyme Corporation Company Details
11.14.2 Genzyme Corporation Business Overview
11.14.3 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Introduction
11.14.4 Genzyme Corporation Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
11.14.5 Genzyme Corporation Recent Development
11.15 GW Pharmaceuticals Plc
11.15.1 GW Pharmaceuticals Plc Company Details
11.15.2 GW Pharmaceuticals Plc Business Overview
11.15.3 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Introduction
11.15.4 GW Pharmaceuticals Plc Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
11.15.5 GW Pharmaceuticals Plc Recent Development
11.16 ImmunoCellular Therapeutics, Ltd.
11.16.1 ImmunoCellular Therapeutics, Ltd. Company Details
11.16.2 ImmunoCellular Therapeutics, Ltd. Business Overview
11.16.3 ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Introduction
11.16.4 ImmunoCellular Therapeutics, Ltd. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
11.16.5 ImmunoCellular Therapeutics, Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol Myers Squibb Company
Cantex Pharmaceuticals Inc
Cavion llc
Celldex Therapeutics Inc
Coherus BioSciences Inc
Cortice Biosciences, Inc.
Eisai Co Ltd
Eli Lilly and Company
EnGeneIC
ERC Belgium SA
GenSpera
Genzyme Corporation
GW Pharmaceuticals Plc
ImmunoCellular Therapeutics, Ltd.
List of Tables
 Table 1. Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of AU-105
 Table 3. Key Players of Axitinib
 Table 4. Key Players of AXL-1717
 Table 5. Key Players of AZD-7451
 Table 6. Key Players of Others
 Table 7. Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2020-2025) & (US$ Million)
 Table 10. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Region (2020-2025)
 Table 11. Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 12. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Region (2026-2031)
 Table 13. Recurrent Glioblastoma Multiforme Treatment Market Trends
 Table 14. Recurrent Glioblastoma Multiforme Treatment Market Drivers
 Table 15. Recurrent Glioblastoma Multiforme Treatment Market Challenges
 Table 16. Recurrent Glioblastoma Multiforme Treatment Market Restraints
 Table 17. Global Recurrent Glioblastoma Multiforme Treatment Revenue by Players (2020-2025) & (US$ Million)
 Table 18. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Players (2020-2025)
 Table 19. Global Top Recurrent Glioblastoma Multiforme Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recurrent Glioblastoma Multiforme Treatment as of 2024)
 Table 20. Ranking of Global Top Recurrent Glioblastoma Multiforme Treatment Companies by Revenue (US$ Million) in 2024
 Table 21. Global 5 Largest Players Market Share by Recurrent Glioblastoma Multiforme Treatment Revenue (CR5 and HHI) & (2020-2025)
 Table 22. Global Key Players of Recurrent Glioblastoma Multiforme Treatment, Headquarters and Area Served
 Table 23. Global Key Players of Recurrent Glioblastoma Multiforme Treatment, Product and Application
 Table 24. Global Key Players of Recurrent Glioblastoma Multiforme Treatment, Date of Enter into This Industry
 Table 25. Mergers & Acquisitions, Expansion Plans
 Table 26. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2020-2025) & (US$ Million)
 Table 27. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Type (2020-2025)
 Table 28. Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 29. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Type (2026-2031)
 Table 30. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2020-2025) & (US$ Million)
 Table 31. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Application (2020-2025)
 Table 32. Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 33. Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Application (2026-2031)
 Table 34. North America Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. North America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 36. North America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Europe Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 39. Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 40. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2020-2025) & (US$ Million)
 Table 42. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2026-2031) & (US$ Million)
 Table 43. Latin America Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 47. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 48. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 49. Boehringer Ingelheim GmbH Company Details
 Table 50. Boehringer Ingelheim GmbH Business Overview
 Table 51. Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Product
 Table 52. Boehringer Ingelheim GmbH Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025) & (US$ Million)
 Table 53. Boehringer Ingelheim GmbH Recent Development
 Table 54. Boston Biomedical, Inc. Company Details
 Table 55. Boston Biomedical, Inc. Business Overview
 Table 56. Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Product
 Table 57. Boston Biomedical, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025) & (US$ Million)
 Table 58. Boston Biomedical, Inc. Recent Development
 Table 59. Bristol-Myers Squibb Company Company Details
 Table 60. Bristol-Myers Squibb Company Business Overview
 Table 61. Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Product
 Table 62. Bristol-Myers Squibb Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025) & (US$ Million)
 Table 63. Bristol-Myers Squibb Company Recent Development
 Table 64. Cantex Pharmaceuticals, Inc. Company Details
 Table 65. Cantex Pharmaceuticals, Inc. Business Overview
 Table 66. Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Product
 Table 67. Cantex Pharmaceuticals, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025) & (US$ Million)
 Table 68. Cantex Pharmaceuticals, Inc. Recent Development
 Table 69. Cavion LLC Company Details
 Table 70. Cavion LLC Business Overview
 Table 71. Cavion LLC Recurrent Glioblastoma Multiforme Treatment Product
 Table 72. Cavion LLC Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025) & (US$ Million)
 Table 73. Cavion LLC Recent Development
 Table 74. Celldex Therapeutics, Inc. Company Details
 Table 75. Celldex Therapeutics, Inc. Business Overview
 Table 76. Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Product
 Table 77. Celldex Therapeutics, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025) & (US$ Million)
 Table 78. Celldex Therapeutics, Inc. Recent Development
 Table 79. Coherus BioSciences, Inc. Company Details
 Table 80. Coherus BioSciences, Inc. Business Overview
 Table 81. Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product
 Table 82. Coherus BioSciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025) & (US$ Million)
 Table 83. Coherus BioSciences, Inc. Recent Development
 Table 84. Cortice Biosciences, Inc. Company Details
 Table 85. Cortice Biosciences, Inc. Business Overview
 Table 86. Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product
 Table 87. Cortice Biosciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025) & (US$ Million)
 Table 88. Cortice Biosciences, Inc. Recent Development
 Table 89. Eisai Company Details
 Table 90. Eisai Business Overview
 Table 91. Eisai Recurrent Glioblastoma Multiforme Treatment Product
 Table 92. Eisai Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025) & (US$ Million)
 Table 93. Eisai Recent Development
 Table 94. Eli Lilly and Company Company Details
 Table 95. Eli Lilly and Company Business Overview
 Table 96. Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Product
 Table 97. Eli Lilly and Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025) & (US$ Million)
 Table 98. Eli Lilly and Company Recent Development
 Table 99. EnGeneIC Ltd Company Details
 Table 100. EnGeneIC Ltd Business Overview
 Table 101. EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Product
 Table 102. EnGeneIC Ltd Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025) & (US$ Million)
 Table 103. EnGeneIC Ltd Recent Development
 Table 104. ERC Belgium SA Company Details
 Table 105. ERC Belgium SA Business Overview
 Table 106. ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Product
 Table 107. ERC Belgium SA Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025) & (US$ Million)
 Table 108. ERC Belgium SA Recent Development
 Table 109. GenSpera, Inc. Company Details
 Table 110. GenSpera, Inc. Business Overview
 Table 111. GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Product
 Table 112. GenSpera, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025) & (US$ Million)
 Table 113. GenSpera, Inc. Recent Development
 Table 114. Genzyme Corporation Company Details
 Table 115. Genzyme Corporation Business Overview
 Table 116. Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Product
 Table 117. Genzyme Corporation Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025) & (US$ Million)
 Table 118. Genzyme Corporation Recent Development
 Table 119. GW Pharmaceuticals Plc Company Details
 Table 120. GW Pharmaceuticals Plc Business Overview
 Table 121. GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Product
 Table 122. GW Pharmaceuticals Plc Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025) & (US$ Million)
 Table 123. GW Pharmaceuticals Plc Recent Development
 Table 124. ImmunoCellular Therapeutics, Ltd. Company Details
 Table 125. ImmunoCellular Therapeutics, Ltd. Business Overview
 Table 126. ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Product
 Table 127. ImmunoCellular Therapeutics, Ltd. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025) & (US$ Million)
 Table 128. ImmunoCellular Therapeutics, Ltd. Recent Development
 Table 129. Research Programs/Design for This Report
 Table 130. Key Data Information from Secondary Sources
 Table 131. Key Data Information from Primary Sources
 Table 132. Authors List of This Report


List of Figures
 Figure 1. Recurrent Glioblastoma Multiforme Treatment Picture
 Figure 2. Global Recurrent Glioblastoma Multiforme Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Type: 2024 VS 2031
 Figure 4. AU-105 Features
 Figure 5. Axitinib Features
 Figure 6. AXL-1717 Features
 Figure 7. AZD-7451 Features
 Figure 8. Others Features
 Figure 9. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2020-2031) & (US$ Million)
 Figure 10. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Application: 2024 VS 2031
 Figure 11. Hospital Case Studies
 Figure 12. Clinic Case Studies
 Figure 13. Others Case Studies
 Figure 14. Recurrent Glioblastoma Multiforme Treatment Report Years Considered
 Figure 15. Global Recurrent Glioblastoma Multiforme Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 16. Global Recurrent Glioblastoma Multiforme Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Region: 2024 VS 2031
 Figure 18. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Players in 2024
 Figure 19. Global Top Recurrent Glioblastoma Multiforme Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recurrent Glioblastoma Multiforme Treatment as of 2024)
 Figure 20. The Top 10 and 5 Players Market Share by Recurrent Glioblastoma Multiforme Treatment Revenue in 2024
 Figure 21. North America Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. North America Recurrent Glioblastoma Multiforme Treatment Market Share by Country (2020-2031)
 Figure 23. United States Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Canada Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Europe Recurrent Glioblastoma Multiforme Treatment Market Share by Country (2020-2031)
 Figure 27. Germany Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. France Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. U.K. Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Italy Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Russia Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Nordic Countries Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Share by Region (2020-2031)
 Figure 35. China Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Japan Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. South Korea Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. India Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Australia Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Latin America Recurrent Glioblastoma Multiforme Treatment Market Share by Country (2020-2031)
 Figure 43. Mexico Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Brazil Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Share by Country (2020-2031)
 Figure 47. Turkey Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Saudi Arabia Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. UAE Recurrent Glioblastoma Multiforme Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. Boehringer Ingelheim GmbH Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
 Figure 51. Boston Biomedical, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
 Figure 52. Bristol-Myers Squibb Company Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
 Figure 53. Cantex Pharmaceuticals, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
 Figure 54. Cavion LLC Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
 Figure 55. Celldex Therapeutics, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
 Figure 56. Coherus BioSciences, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
 Figure 57. Cortice Biosciences, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
 Figure 58. Eisai Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
 Figure 59. Eli Lilly and Company Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
 Figure 60. EnGeneIC Ltd Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
 Figure 61. ERC Belgium SA Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
 Figure 62. GenSpera, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
 Figure 63. Genzyme Corporation Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
 Figure 64. GW Pharmaceuticals Plc Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
 Figure 65. ImmunoCellular Therapeutics, Ltd. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2020-2025)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Global Gynecological Cancers Drug Market Research Report 2025
Global Treatment Planning Software Market Research Report 2025
Global Kidney Cancer Diagnosis Market Research Report 2025
Global Medicines for Alzheimer Disease Treatment Market Research Report 2025
Global Still s Disease Treatment Market Research Report 2025
Global Prostate Cancer Diagnostics and Therapy Market Research Report 2024
Global Combination Therapy Drug Market Research Report 2025
AI for Cancer Diagnosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Brain Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Diagnostic Guidewire Market Research Report 2024
Global Radiotherapy Device Market Research Report 2024
Novel Drug Delivery Systems for Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global AI Image assisted Diagnosis Software Market Research Report 2025
Global Specific Learning Disability Treatment Market Research Report 2025
Global CGT Drugs Market Research Report 2025
Global Pharmaceutical Asset Management Market Research Report 2025
Global Chronic Kidney Disease Drugs Market Research Report 2025
Prostate Cancer Treatment Device Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ophthalmology AI assisted Diagnosis Software Market Research Report 2024
Global Pharmaceutical Validation Services Market Research Report 2025

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28I6901
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22R9736
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29A2598
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions